Skip links

News

The Battle against glioblastoma: classifying molecular profiles for precision medicine

A transformative study has provided a profound understanding of glioblastoma’s molecular subtypes, revealing the nuances of cellular heterogeneity and the mechanisms behind resistance to treatment. This critical research not only enhances our comprehension of this aggressive cancer but also opens new frontiers for the precision-targeting

Drug bypasses suppressive immune cells to unleash immunotherapy

By recruiting the immune system to combat tumor cells, immunotherapy has improved survival rates, offering hope to millions of cancer patients. However, only about one in five people responds favorably to these treatments. Credit: Matt Miller/WashU Medicine By recruiting the immune system to combat tumor

Targeted cancer therapy: initial high concentration may slow down selection for resistance

BUFFALO, NY- August 6, 2024 – On July 28, 2024, Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center published a new editorial in Volume 16, Issue 14 of Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science), entitled, “Targeted cancer therapy: the initial high concentration

AI model effective in detecting prostate cancer

OAK BROOK, Ill. – A deep learning model performs at the level of an abdominal radiologist in the detection of clinically significant prostate cancer on MRI, according to a study published today in Radiology, a journal of the Radiological Society of North America (RSNA). The

Early menopause linked to increased breast cancer risk

Some who experience menopause early may be at increased risk for developing breast cancer, according to research led by scientists at Huntsman Cancer Institute at the University of Utah (the U) and the Spencer Fox Eccles School of Medicine at the U. Credit: Huntsman Cancer Institute

Improved chemokine homing enhances CAR T–cell therapy for osteosarcoma

(MEMPHIS, Tenn. – August 5, 2024) Chimeric antigen receptor (CAR) T–cell immunotherapy re-engineers a patient’s immune cells to target cancer cells. While successful in some types of leukemia, the approach has yet to realize its potential against pediatric solid tumors. Scientists at St. Jude Children’s
Explore
Drag